Skip to main content
  • Home
  • Issues
    • Current Issue
    • All Issues
    • Accepted Articles
    • Online First
    • Supplement
    • CME
  • About
  • For Authors
    • Instructions for Authors
    • Submission Fee
    • Submit Manuscript
  • Podcasts

Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients

< Back to Listing

Share this Article

Singapore Med J 2008; 49(1): 26-30
Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients

  • Abstract
  • PDF

Hamidah A, Rizal A M, Nordiah A J, Jamal R
Correspondence: Dr Hamidah Alias, midalias@mail.hukm.ukm.my

ABSTRACT
Introduction We evalutated piperacillin-tazobactam in association with amikacin in the initial empirical therapy of febrile neutropenic children.
Methods An open-labelled, non-randomised, prospective trial to assess the efficacy and safety of this association was conducted from June 1, 2001 to December 31, 2002. Children and adolescents were treated for a haematological  mal ignancy or  a primary, refractory or relapsed solid tumour, and presented with febrile neutropenia. Patients received intravenous piperacillin-tazobactam (90 mg/kg/dose every eight hours) plus a single daily dose of  amikacin at 15 mg/kg/day, maximum 250 mg. If fever persisted, second line therapy with carbapenem was  administered. Teicoplanin was added for grampositive isolates or for unremitting fever after 48 hours, if clinically indicated. Amphotericin B was added at 96 hours, if fever and neutropenia persisted.
Results 155 episodes of fever and neutropenia in 76 patients were evaluable. 40 (25.8 percent) episodes were a microbiologically-documented infection, 30 (19.4 percent) were clinicallydocumented,  and 85  (54.8 percent) were unexplained fever. 77 (49.7 percent) episodes responded to piperacillin-tazobactam plus amikacin without a need for tretment modification. A higher success rate (63.5 percent) was observed in episodes with unexplained fever. The predominant pathogens isolated in our study were gram-negative organisms (70.7 percent). A mild gastrointestinal intolerance occurred in 35 out of 155 (22.6 percent) episodes.
Conclusions This study suggests that piperacillin-tazobactam plus amikacin presents a satisfactory efficacy and a good tolerance as initial empirical therapy for febrile neutropenic children.

Keywords: amikacin, childhood cancer, febrile neutropenia, piperacillin-tazobactam
Singapore Med J 2008; 49(1): 26-30

http://smj.org.sg/sites/default/files/4901/4901a3.pdf
×
POPULAR THIS MONTH
Eating disorders in children and adolescents
Computed tomography findings of abnormal gas in the abdomen and pelvis
Singapore Advanced Cardiac Life Support Guidelines 2021
Validation of the kidney failure risk equation in predicting the risk of progression to kidney failure in a multi-ethnic Singapore chronic kidney disease cohort

Around the Site

Home

About SMJ

For Reviewers

Sign Up for Alerts

Issues

Current Issue

All Issues

Online First

Supplement

CME

For Authors

Instructions for Authors

Submit Manuscript


Follow us on:
        

More Links

Contact Us

Copyright

Advertise

SMJ Forms

Privacy Policy

SMA Home

Copyright 2021. Singapore Medical Association. All Rights Reserved.